Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Turner, Charles Cantor, Erik Wallden, Peter Tattle, Patrick Zenner


Stephen Turner, 58, the co-founder, chairman, and chief executive officer of Frederick, Md.-based Clinomics, will become a non-executive director of Cambridge, UK-based Cytomyx, upon the completion of the acquisition of Clinomics by Cytomyx, the company said. Turner will oversee US operations and business development in the US market.

Charles Cantor will join the scien-tific advisory board of St. Joseph, Mich.-based GeneGo, a bioinformatics firm. Cantor is currently chief scientific officer and a board member of Sequenom. He is also director of the Center for Advanced Biotechnology at Boston University. Cantor has held positions at Columbia University and the University of California at Berkeley, and was director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. In 2002, he founded SelectX Pharmaceuticals.

Erik Wallden will head marketing and business development for Biacore International from Neuchatel, Switzerland, as executive vice president, taking a new position that reports to the president and chief executive officer of the Uppsala, Sweden-based company. Wallden will begin work on Jan. 19. Wallden previously was president and CEO of Pyrosequencing, a position he held since 1997. Previously, he held various R&D and marketing positions within Pharmacia Biotechnology (today Amersham Biosciences), before he was appointed vice president worldwide marketing, sales and support at Pharmacia Biosensor, whose name was changed to Biacore in conjunction with the company’s initial public offering in 1989.

Peter Tattle joins the board of directors of Genta, a Berkeley Heights, NJ-based company. Tattle was previously chairman for pharmaceuticals in the Americas for Johnson & Johnson before retiring in 2001. Tattle currently serves on the boards of Xanthus Life Sciences, DFB Pharmaceuticals, Catalina Marketing, and the Cancer Institute of New Jersey. He replaces Patrick Zenner, who resigned from Genta’s board. Genta is developing RNA and DNA-based medicines.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.